Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111640 | 0.93 | GPR119 (0.43) | GPR119SLC2A1PIM1MEN1KMT2A | |
| SCHEMBL4122387 | 0.90 | SLC2A1 (0.54) | GPR119SLC2A1MEN1KMT2AHDAC1 | |
| SCHEMBL4122503 | 0.88 | GPR119 (0.47) | GPR119SLC2A1MEN1KMT2ACCR5 | |
| SCHEMBL4126535 | 0.87 | GPR119 (0.47) | GPR119SLC2A1MEN1KMT2AABHD6 | |
| SCHEMBL4117193 | 0.86 | SLC2A1 (0.50) | GPR119SLC2A1MEN1KMT2AHDAC1 | |
| SCHEMBL4116149 | 0.85 | SLC2A1 (0.53) | GPR119SLC2A1MEN1KMT2AHDAC1 | |
| SCHEMBL4126538 | 0.83 | GPR119 (0.44) | GPR119SLC2A1MEN1KMT2ACCR5 | |
| SCHEMBL4117155 | 0.82 | SLC2A1 (0.48) | GPR119SLC2A1MEN1KMT2AHDAC1 | |
| SCHEMBL6207789 | 0.82 | MEN1 (0.49) | GPR119SLC2A1MEN1KMT2AHDAC1 | |
| SCHEMBL4123371 | 0.82 | SLC2A1 (0.49) | GPR119SLC2A1MEN1KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | GPR119 66/4885SLC2A1 3455/4885PIM1 2874/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | GPR119 66/4885SLC2A1 3455/4885PIM1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.